Improving Type 2 Diabetes Healthcare through Personalized Inflammation-Based Interceptive Medicine – INTERCEPT-T2D

Nicolas VENTECLEF (Institut National de la Santé et de la Recherche Médicale)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

CNRS / Université de Lille 2 / Institut Pasteur de Lille
University of Verona
German Diabetes Center
University of Basel
INSERM - UMR 1151 Institut National de la Santé et de la Recherche Médicale
University of Parma
Karolinska Institutet
German Diabetes Center

Help of the ANR 29,999 euros
Beginning and duration of the scientific project: - 24 Months

• List of selected projects
• Permanent link to this summary on the ANR website (ANR-21-MRS2-0012)
• See the publications in the HAL-ANR portal